Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Aug 28, 2025
Application for quotation of securities - NEU
Aug 27, 2025
Investor Presentation, 27 August 2025
Aug 27, 2025
H1 2025 profit after tax A$15m, up from A$8m in H1 2024
Aug 27, 2025
Half Yearly Report and Accounts
Aug 25, 2025
First site initiated for Neuren's PMS Phase 3 trial
Aug 12, 2025
Application for quotation of securities - NEU
Aug 08, 2025
Neuren adds SYNGAP1-related disorder to NNZ-2591 pipeline
Aug 07, 2025
DAYBUE Q2 2025 net sales US$96.1 million up 14% from Q2 2024
Jul 22, 2025
Change of Director's Interest Notice - J Pilcher
Jul 22, 2025
Application for quotation of securities - NEU
1
2
3
4
5
6
7
8
9
10
11
12
Next
